Anti-IL-TIF antibodies
AssigneeZymoGenetics, Inc.
InventorsWenfeng Xu, Wayne R. Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
Life of this patent
Estimating the term…
Abstract
The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
Claims16
A monoclonal antibody, or antigen binding fragment thereof, comprising the heavy and light chain variable regions of an antibody produced from a hybridoma selected from the group consisting of:
- (a) the hybridoma clone 266.16.1.4.4.1 (ATCC PTA-5035);
- (b) the hybridoma clone 266.5.1.2.2.3 (ATCC PTA-5033);
- (c) the hybridoma clone 267.17.1.1.4.1 (ATCC PTA-5038);
- (d) the hybridoma clone 267.4.1.1.4.1,(ATCC PTA-5037);
- and (e) the hybridoma clone 266.12.6.1.3.2.1 (ATCC PTA-5034);
- and (e) the hybridoma clone 266.19.1.10.5.2,(ATCC PTA-5036).
A monoclonal antibody, or antigen binding fragment thereof, comprising the heavy and light chain CDR1, CDR2, and CDR3 regions of an antibody produced from a hybridoma selected from the group consisting of:
- (a) the hybridoma clone 266.16.1.4.4.1 (ATCC PTA-5035);
- (b) the hybridoma clone 266.5.1.2.2.3 (ATCC PTA-5033);
- (c) the hybridoma clone 267.17.1.1.4.1 (ATCC PTA-5038);
- (d) the hybridoma clone 267.4.1.1.4.1 (ATCC PTA-5037);
- and (e) the hybridoma clone 266.12.6.1.3.2.1 (ATCC PTA-5034);
- and (e) the hybridoma clone 266.19.1.10.5.2 (ATCC PTA-5036).
Dependencies are inferred from the claim text.